Insider selling
Traded May 14, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
A major shareholder of Neuropace sold $2.12M of Neuropace shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded May 14, 2025 · Filed May 16, 2025
A major shareholder of Neuropace sold $542K of Neuropace shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$541,960
Shares × reported transaction price
1 day after results of May 13, 2025, 90 days before results of Aug 12, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider selling
Traded May 14, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
A major shareholder of Neuropace sold $2.12M of Neuropace shares. The filing does not indicate a pre-arranged trading plan.
Martha Morrell (CHIEF MEDICAL OFFICER) sold ~$1.07M of Neuropace
Planned saleInsider selling
Traded Feb 20, 2025 · filed the same dayNot reported under a pre-arranged trading plan
A major shareholder of Neuropace sold $49.5M of Neuropace shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.